prednisolone

P1/2, N=18, Completed, University of Colorado, Denver | Active, not recruiting --> Completed

P2, N=171, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2027 --> Dec 2028 | Initiation date: Oct 2024 --> Jan 2025 | Trial primary completion date: Dec 2027 --> Dec 2028

Patients with VEXAS syndrome required high-dose glucocorticoids to achieve remission, and complications-such as malignancy, thrombosis, and infection-occurred frequently within a short observation period.

P2, N=60, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting | Trial completion date: Jan 2026 --> Apr 2029 | Trial primary completion date: Jan 2026 --> Apr 2029

P2/3, N=60, Active, not recruiting, Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Trial primary completion date: Dec 2023 --> Sep 2024

P2, N=110, Active, not recruiting, Changi General Hospital | Recruiting --> Active, not recruiting

Eighteen months before symptom onset, the treatment was changed from afatinib (20 mg/day) to osimertinib (80 mg/day) because of tumor progression...Osimertinib was reduced to 40 mg/day, and oral prednisolone was started at 30 mg/day...Osimertinib, a third-generation tyrosine kinase inhibitor, can be used to treat advanced non-small cell lung cancer with epidermal growth factor receptor mutation-induced bilateral HORV. This adverse effect can be managed with systemic and local steroid treatment and continued osimertinib administration.

P=N/A, N=0, Withdrawn, Australasian Leukaemia and Lymphoma Group | N=130 --> 0 | Unknown status --> Withdrawn

A 92-year-old Japanese man who had been taking oral prednisolone for an IgG4-related respiratory disease visited our clinic...IFN-γ producing type 1 T helper (Th1) cells play an important role in the defense against fungal infections, however, corticosteroids specifically suppress Th1 cell responses and promote the induction of fungal infection. Measurement of PHA-stimulated LTT and serum IFN-γ may be useful in determining the severity and prognosis of deep-seated dermatomycosis in patients undergoing corticosteroid treatment.

P2, N=40, Not yet recruiting, Shanghai BDgene Co., Ltd.

P1, N=16, Recruiting, Shanghai BDgene Co., Ltd.

P2, N=80, Not yet recruiting, Chang Gung Memorial Hospital

A 50 year-old woman was referred to us with a 2-month history of vitritis in both eyes, poorly responding to oral prednisolone...During the disease course, optical coherence tomography of the macula showed a BALAD in the right eye, which resolved during follow-up. Our case indicates that BALAD is a possible rare manifestation of PVRL, and this should be considered in the differential diagnosis process in order to avoid diagnostic delays.

P2, N=10, Recruiting, Alfred Health | Not yet recruiting --> Recruiting

P3, N=244, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2028 --> Sep 2027 | Trial primary completion date: Dec 2028 --> Sep 2027

P4, N=490, Recruiting, Leiden University Medical Center | Phase classification: P2 --> P4

However, the patient reported a severe headache following treatment with oral prednisolone and tacrolimus. Tacrolimus was discontinued, and mycophenolate mofetil was instead administered with a favorable outcome. Mycophenolate mofetil should therefore be considered as an alternative treatment for anti-MDA-5-positive interstitial lung disease in cases where calcineurin inhibitors cannot be used.

P3, N=1202, Completed, University College, London | Active, not recruiting --> Completed | Trial completion date: May 2023 --> May 2024

P2, N=171, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Apr 2024 --> Jul 2024

P4, N=78, Recruiting, First Affiliated Hospital, Sun Yat-Sen University | Not yet recruiting --> Recruiting | Trial completion date: Aug 2025 --> Dec 2026 | Trial primary completion date: Aug 2025 --> Sep 2026

Although cutaneous Rosai-Dorfman disease is considered benign and well medical responded disease, patients with atypical presentation and rapid growing lesion may necessitate aggressive multimodal treatment.

P2, N=171, Not yet recruiting, National Cancer Institute (NCI)

P4, N=138, Active, not recruiting, Erasmus Medical Center | Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Jul 2026 | Trial primary completion date: Jun 2023 --> Jul 2024

P=N/A, N=120, Not yet recruiting, Cairo University

P4, N=100, Completed, Erasmus Medical Center | Active, not recruiting --> Completed

P3, N=14, Terminated, European Organisation for Research and Treatment of Cancer - EORTC | N=185 --> 14 | Trial completion date: Mar 2027 --> Nov 2023 | Recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Sep 2023; Withdrawal grant provider

P4, N=71, Active, not recruiting, University of Aarhus | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> May 2025 | Trial primary completion date: Dec 2024 --> Feb 2024

P=N/A, N=104, Recruiting, Postgraduate Institute of Medical Education and Research | Trial primary completion date: Dec 2023 --> Dec 2024

P2, N=490, Recruiting, Leiden University Medical Center | Not yet recruiting --> Recruiting

P2, N=158, Active, not recruiting, University of Oxford | Recruiting --> Active, not recruiting

P3, N=56, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting

P3, N=300, Recruiting, Postgraduate Institute of Medical Education and Research

P2, N=490, Not yet recruiting, Leiden University Medical Center | Initiation date: Oct 2023 --> Jan 2024

P3, N=547, Terminated, Bayer | The addition of copanlisib to standard immunochemo therapy did not improve progression-free survival compared to the control arm. Base on the study results, company decided to terminate the study.

P=N/A, N=136, Recruiting, Marieke Duiverman | Trial completion date: Jul 2023 --> Dec 2025 | Trial primary completion date: May 2023 --> Oct 2025

P3, N=56, Recruiting, AbbVie | Trial primary completion date: Aug 2027 --> Apr 2024

P1/2, N=142, Recruiting, Eisai Inc. | N=66 --> 142

P3, N=56, Recruiting, AbbVie | Trial primary completion date: Apr 2024 --> Aug 2027

P3, N=250, Completed, Australasian Leukaemia and Lymphoma Group | Active, not recruiting --> Completed

Finally, she was diagnosed with TAMA and treated with oral prednisolone, intravenous immunoglobulin. Chemotherapy for thymoma was continued by using carboplatin and paclitaxel... TAMA is a poor prognostic factor for thymoma patients. It is considered necessary for disease control of TAMA to reduce the volume of thymoma as much as possible by thymectomy and chemotherapy. Narrowband-UVB is known to enhance the regulatory T cell proliferation, and it has been reported that narrowband-UVB is highly effective in acute GVHD skin lesions.

P1/2, N=80, Active, not recruiting, Peter MacCallum Cancer Centre, Australia | Recruiting --> Active, not recruiting